Top Banner
HIV and Malaria Dr Jane Achan Dept of Pediatrics, Makerere University College of Health Sciences Prof. Moses Kamya Makerere University College of Health Sciences 6 th IAS CONFERENCE, 18 th July 2011
25

HIV and Malaria

Feb 24, 2016

Download

Documents

jamar

HIV and Malaria. Dr Jane Achan Dept of Pediatrics, Makerere University College of Health Sciences. Prof. Moses Kamya Makerere University College of Health Sciences. 6 th IAS CONFERENCE, 18 th July 2011. Burden of malaria . Over 300 million clinical cases and 1 million deaths annually - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: HIV and Malaria

HIV and Malaria

Dr Jane AchanDept of Pediatrics, Makerere University

College of Health Sciences

Prof. Moses KamyaMakerere University College of Health

Sciences6th IAS CONFERENCE, 18th July 2011

Page 2: HIV and Malaria

Burden of malaria • Over 300 million

clinical cases and 1 million deaths annually

• Accounts for 25-40% of outpatient visits and 20-50% of hospital admissions

Page 3: HIV and Malaria

HIV and Malaria in Sub-Saharan Africa

HIV distribution Malaria distribution

Page 4: HIV and Malaria

Epidemiological overlap: Why does this matter?

• Any interaction could be of great pubic health importance:– Malaria could accelerate HIV disease progression and facilitate

HIV transmission

– HIV infection could disrupt immune responses to malaria and may increase incidence and severity of malaria

– Routine interventions for HIV may impact upon the incidence of malaria

– Therapies for each infection may impact upon the other, leading to unanticipated effects on drug efficacy or toxicity

Page 5: HIV and Malaria

Plausibility of interaction:Malaria affecting HIV

Antigen stimulation Immune activation

Faster disease progression

Increased viral replication

Page 6: HIV and Malaria

HIV Viral load changes during malaria.

Hoffman et al , AIDS. 13(4):487-494, March 11, 1999.

Page 7: HIV and Malaria

Influence of malaria on HIV disease• Increased viral load during malaria might be sustained for long enough

to increase risk of HIV transmission and accelerated disease progression.

• Parasitemia and clinical malaria are associated with 0.25-0.89 log increase in viral load for about 9 weeks

• Treatment of malaria in HIV-infected adults is associated with decreased viral load (190000 to 120000 copies/ml)

Kublin, et al, Lancet 2005;365:233-239; ter Kuile, et al, Am J Trop Med Hyg 2004;71:41-54; Van Geertruyden, et al,JAIDS 2006;43:363-7; Hoffman, et al,AIDS 1999;13:487-495; Mermin, et al, JAIDS 2006;41:129-130, Brahmbhatt, etal, AIDS 2003; 17: 2539-41; Ayisi, et al, AIDS 2003; 17: 585-94; Ned, et al, Trends Parisitol 2005;24: 285-91., tatfeng etat, J Vector Borne Dis 44, June 2007

Page 8: HIV and Malaria

Influence of malaria on HIV disease

• Malaria associated with more rapid decline in CD4 cell count– Mean difference in CD4 cell decline per additional episode of malaria was 40

cells/µL/year (Mermin et al, JAIDS 2006;41:129-130)

• However evidence that malaria has an impact on HIV disease progression is limited

• Transient and repeated increases in HIV viral load from recurrent co-infection with malaria may contribute to promoting the spread of HIV in sub-Saharan Africa.– Modelling in Kisumu, Kenya indicated a 2.1% increase in HIV prevalence

since 1980.

Abu-Raddad, et al, Science 2006;314:1603-1606;

Page 9: HIV and Malaria

HIV and malaria in pregnancy

• Pregnant women are at increased risk for malaria, especially in their first 2 pregnancies.

• Estimated that the HIV epidemic results in an additional 500,000 to 1 million women per year who have malaria during pregnancy

● HIV infected pregnant women are at increased risk of:– Symptomatic malaria and placental malaria– Severe malaria– Maternal anemia and adverse birth outcomes

Malaria infection placental malaria low birth weight infant mortality

maternal anemia

Page 10: HIV and Malaria

0

10

20

30

40

50

60

malaria incidence

HIV(+) HIV(-)

G1>G2

Total n = 414: Kisumu, Kenya, 1994-1996 (CDC Studies)

Gravidity-related pattern of Malaria in pregnancy is altered by HIV

Page 11: HIV and Malaria

Gravidity-related pattern of Malaria in pregnancy ● The gravidity-related pattern of Malaria in

pregnancy is altered by HIV so that the burden is shifted from primigravidae to all pregnant women

● Possible mechanism: HIV may affect memory immune mechanism in pregnant women → parity dependent acquisition of anti-malarial immunity

Page 12: HIV and Malaria

MTCT and Infant outcomes

• Infant Mortality Rate (IMR) increases in HIV+ pregnant women with malaria

• Mother to child transmission (MTCT) of HIV increased when women had placental Malaria • Brahmbhatt, et al, AIDS 2003; 17: 2539-41; Ayisi, et al, AIDS 2003; 17: :

585-94

• Postnatal death in infants is higher amongst HIV positive women with placental malaria compared to HIV positive women (Odds Ratio: 3 – 7.7; Bloland, Malawi .95)

Page 13: HIV and Malaria

SP- IPT versus CTX for prevention of malaria in pregnancy

Page 14: HIV and Malaria

“Combination prevention” for malaria in HIV infected populations.

● Cotrimoxazole prophylaxis (CTX)

● Insecticide treated bed nets (ITNs)

● ART

Page 15: HIV and Malaria

Malaria incidence among HIV-infected adults

● 95% reduction in malaria with all 3 interventions

0

10

20

30

40

50

60

Cotrim Cotrim and ART Cotrim, ART, andbednets

Malaria per 100 person-years

Page 16: HIV and Malaria

Effect of CTX and ITN use on malaria incidence (Kamya et al. AIDS 2007)

Exposure Group IRR (95% CI) P-value

No CTX, No ITN Reference group

CTX prophylaxis alone 0.65 (0.27-1.57) 0.34

ITN alone 0.56 (0.45-0.70) <0.001

Both CTX and ITN 0.03 (0.01-0.11) <0.001

Page 17: HIV and Malaria

Protective efficacy of CTX in Kampala over time

Time period Malaria incidence (PPY) Protective efficacy IRR (95% CI)*

No TS TS

Aug 06-Jan 07 0.11 0.71 0.16 (0.09-0.27)

Feb 07-Jul 07 0.14 0.51 0.28 (0.16-0.46)

Aug 07 – Jan 08 0.09 0.38 0.24 (0.13-0.46)

* Test for trend: p-value = 0.35

Page 18: HIV and Malaria

Prophylactic effect of CTX against malaria in contrasting transmission settings

Site CTX use

Episodes of malaria

Person time

Incidence of malaria

(PPY)

IRR(95% CI)

Kampala*

No CTX

389 727 0.540.20

(0.13-0.30)CTX 49 423 0.12

Tororo‡

No CTX

121 44.1 2.740.27

(0.19 -0.40)CTX 45 66.3 0.68

*low-medium transmission site; ‡ very high transmission site

Page 19: HIV and Malaria

Clinical implications

● Malaria is rarely the cause of fever in individuals receiving CTX

● Malaria accounted for only 4% of febrile episodes in an HIV- infected cohort compared to 33% in the HIV- uninfected cohort (p < 0.0001). Kamya et al, AIDS, 2007

● Presumptive therapy for malaria in these groups should be avoided and careful evaluation for other causes of fever should be done

Page 20: HIV and Malaria

Are we creating resistance?

020406080

100

mutations

Kampala No TS Kampala TS Tororo No TS Tororo TS

Page 21: HIV and Malaria

HIV and Malaria Interactions

DON’T FORGET THE DRUGS!

Page 22: HIV and Malaria

AQ/AS

AL

AQ Exposure ¹Liver Function Tests ¹

Moderate to severe neutopenia ²

HIV Infected Children

Antiretrovirals(nucleosideanalogues)

On going study

Healthy Volunteers Efavirenz

Efavirenz

Healthy Volunteers

Lopinavir / ritonavir

Healthy Volunteers

Lumefantrine ³Exposure(200%)

¹ German, etal CID, 2007² Gasasira, etal CID, 2008³ German, etal 15th Croi, 2008

Page 23: HIV and Malaria

Conclusions

● Significance of the impact of malaria on HIV disease progression remains to be determined especially in this era of malaria preventive strategies.

● Malaria prevention in pregnancy is critical to minimize adverse pregnancy outcomes.

● There is strong evidence for the impact of combination prevention against malaria in HIV infected populations

● Attention to drug-drug interactions is critical as new antimalarial and antiretroviral drugs are rolled out.

Page 24: HIV and Malaria

Acknowledgements● Makerere University-University of California San

Francisco (MU-UCSF) Research Collaboration:– Diane Havlir– Edwin Charlebois– Grant Dorsey– Philip J Rosenthal

● Sponsors: NIH, NICHD, CFAR

● Staff, Patients and caretakers that contribute to these studies

Page 25: HIV and Malaria

Thank You